Neuropace cut 2026 revenue guidance to $91 million to $92 million from $99.5 million to $101.5 million after third-quarter revenue declined 1.1 percent to $23.1 million. It expects approximately 15% R&S revenue growth in 2027, excluding IGE expansion.
NPCE · NeuroPace Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
NeuroPace said the FDA found its PMA-S for drug-resistant idiopathic generalized epilepsy not approvable in its current form. After meeting with the FDA, it is adding NAUTILUS data and context; nine-month revenue rose 11% to $67.9 million.
NeuroPace reported third-quarter revenue of $23.1 million for the quarter ended September 30, 2026, saying results fell below expectations, and cut full-year 2026 revenue guidance to $91 million to $92 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. Third-quarter RNS revenue grew only 1.4%, while 2026 revenue and adjusted EBITDA guidance were revised lower. Offsetting this, adjusted EBITDA improved to a $0.4 million gain, and management projects approximately 15% full-year RNS revenue growth in 2027 alongside IGE, Remote Care, Aurora and reimbursement catalysts.
- + Management expects approximately 15% full-year RNS revenue growth in 2027. new
- + Adjusted EBITDA improved to a $0.4 million gain from a $1.3 million loss.
- + The IGE PMA supplement could support potential FDA approval by mid-year 2027. new
- + Remote Care was submitted to the FDA ahead of the previously communicated year-end timeline. new
- + The Aurora real-world evidence study was initiated to support potential adolescent focal-epilepsy indication expansion. new
- + A reimbursement increase for RNS replacement procedures is expected to provide an ongoing tailwind. new
- − Third-quarter RNS revenue grew only 1.4%. new
- − Full-year 2026 revenue guidance was revised down to $91 million–$92 million from $99.5 million–$101.5 million. new
- − Changes to sales leadership and field roles disrupted territories and affected results in certain accounts. new
- − Customer concentration made disruptions at several large accounts disproportionately important to revenue. new
- − Service revenue declined to $203,000 from $771,000 and more than offset RNS revenue growth. new
- − Full-year adjusted EBITDA loss guidance was revised to $8.5 million–$9.5 million from $7.5 million–$8.5 million. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA from continuing operations (Non-GAAP) non-GAAP | -6.04M | Six Months Ended June 30, 2026 | — |
| Non-GAAP cost of goods sold non-GAAP | 7.65M | Six Months Ended June 30, 2026 | — |
| Non-GAAP general and administrative expense non-GAAP | 8.14M | Six Months Ended June 30, 2026 | — |
| Non-GAAP gross margin non-GAAP | 83.4% | Q2 2026 | — |
| Non-GAAP loss from continuing operations non-GAAP | -6.17M | Six Months Ended June 30, 2026 | — |
| Non-GAAP loss from operations non-GAAP | -$2.8M | Q2 2026 | — |
| Non-GAAP net loss non-GAAP | -$3.9M | Q2 2026 | — |
| Non-GAAP net loss from continuing operations non-GAAP | -8.35M | Six Months Ended June 30, 2026 | — |
| Non-GAAP operating expenses non-GAAP | 43.35M | Six Months Ended June 30, 2026 | — |
| Non-GAAP research and development expense non-GAAP | 12.75M | Six Months Ended June 30, 2026 | — |
| Non-GAAP sales and marketing expense non-GAAP | 22.46M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NPCE
this stock
NeuroPace Inc
|
$274.58M | -48.4% | +25.1% | — | 2.5% |
|
ABT
Abbott Laboratories
|
$186.10B | -14.2% | +5.7% | 40.1 | 1.1% |
|
MDT
Medtronic plc
|
$131.60B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$118.29B | -11.6% | +11.2% | 33.1 | 1.7% |
|
BSX
Boston Scientific Corp
|
$63.33B | -54.2% | +12.5% | 18.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 16
NeuroPace reported third-quarter revenue of $23.1 million for the quarter ended September 30, 2026, saying results fell below expectations, and cut full-year 2026 revenue guidance to $91 million to $92 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NPCE | -39.3% | -37.6% | -53.3% | -35.2% | -48.4% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -37.6% | -34.1% | -51.9% | -33.1% | -56.9% |